<a href="https://www.fiercebiotech.com/biotech/biocryst-culls-eye-disease-candidate-after-second-attempt-find-indication" hreflang="en">BioCryst scraps eye candidate to focus on rare diseases</a>
BioCryst Pharmaceuticals has discontinued the development of avoralstat, initially aimed at treating diabetic macular edema, to concentrate on rare diseases, particularly Netherton syndrome. The decision follows a history of unsuccessful trials for avoralstat, which was previously explored for hereditary angioedema but ultimately led to the successful launch of another drug, Orladeyo.
BioCryst Pharmaceuticals' decision to halt the development of avoralstat for diabetic macular edema and refocus on rare diseases underscores the strategic importance of concentrating resources on niche markets where there is less competition and higher unmet needs. This pivot highlights an actionable trend for stakeholders in healthtech and biotech to prioritize rare disease pipelines, potentially offering more lucrative opportunities and streamlined paths to FDA approval due to the Orphan Drug Act incentives.